JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 13, 2004; DOI: 10.1124/jpet.103.061846


0022-3565/04/3091-425-431$20.00
JPET 309:425-431, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.061846v1
309/1/425    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andresen, B. T.
Right arrow Articles by Jackson, E. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andresen, B. T.
Right arrow Articles by Jackson, E. K.

CELLULAR AND MOLECULAR

AT2 Receptors Attenuate AT1 Receptor-Induced Phospholipase D Activation in Vascular Smooth Muscle Cells

Bradley T. Andresen1, Guillermo G. Romero, and Edwin K. Jackson

Department of Pharmacology (B.T.A., G.G.R., E.K.J.) and Center for Clinical Pharmacology (B.T.A., E.K.J.), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Previous studies indicate that angiotensin (AT)1 receptor-induced activation of phospholipase D (PLD) may importantly contribute to vascular hypertrophy, injury, and contraction. However, the role of AT2 receptors in regulating AT1 receptor-induced PLD activation is unknown. In this study, we identified angiotensin II receptors on cultured preglomerular vascular smooth muscle cells (PGSMCs) from spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY) by reverse transcription-polymerase chain reaction (RT-PCR) and binding assays and examined their functional effects on angiotensin II-mediated PLD activity. Both RT-PCR and binding indicated that cultured SHR and WKY PGSMCs expressed AT1 and AT2 receptors, and the combined total of AT1 and AT2 receptors was similar between the strains. However, the number of AT1 and AT2 receptors differed between SHR and WKY PGSMCs in so much as the ratio of AT1 to AT2 receptors was approximately 1 to 1 and 3 to 1 in WKY and SHR PGSMCs, respectively. As previously reported, angiotensin II more potently activated PLD in SHR PGSMCs (SHR EC50 = 4 nM; WKY EC50 = 47 nM). Addition of an AT2 receptor-specific antagonist or agonist shifted the angiotensin II-mediated PLD concentration-response curve of WKY PGSMCs in a manner consistent with AT2 receptors producing an inhibitory signal. In contrast, in SHR little change was observed. Our findings indicate that the ratio of AT1 to AT2 receptors in vascular smooth muscle cells may be a determinant of the net effects of angiotensin II on PLD activity due to AT2-dependent inhibition of AT1-mediated PLD activity. Furthermore, cultured WKY PGSMCs provide an excellent model system to study endogenous AT2 receptor signal transduction.


Received October 19, 2003; accepted December 5, 2003.

Address correspondence to: Dr. Edwin K. Jackson, The Center for Clinical Pharmacology, 623 Scaife Hall, University of Pittsburgh School of Medicine, 3550 Terrace St., Pittsburgh, PA 15261. E-mail: edj{at}pitt.edu




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. K. Stennett, X. Qiao, A. E. Falone, V. V. Koledova, and R. A. Khalil
Increased vascular angiotensin type 2 receptor expression and NOS-mediated mechanisms of vascular relaxation in pregnant rats
Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H745 - H755.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Salim, K. M. Standifer, and D. C. Eikenburg
Extracellular Signal-Regulated Kinase 1/2-Mediated Transcriptional Regulation of G-Protein-Coupled Receptor Kinase 3 Expression in Neuronal Cells
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 51 - 59.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J.-H. Parmentier, Z. Pavicevic, and K. U. Malik
ANG II stimulates phospholipase D through PKC{zeta} activation in VSMC: implications in adhesion, spreading, and hypertrophy
Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H46 - H54.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. E. Jalil, A. Perez, M. P. Ocaranza, J. Bargetto, A. Galaz, and S. Lavandero
Increased Aortic NADPH Oxidase Activity in Rats With Genetically High Angiotensin-Converting Enzyme Levels
Hypertension, December 1, 2005; 46(6): 1362 - 1367.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Guimaraes and H. Pinheiro
Functional evidence that in the cardiovascular system AT1 angiotensin II receptors are AT1B prejunctionally and AT1A postjunctionally
Cardiovasc Res, August 1, 2005; 67(2): 208 - 215.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
A. A. Banday, A. H. Siddiqui, M. M. Menezes, and T. Hussain
Insulin treatment enhances AT1 receptor function in OK cells
Am J Physiol Renal Physiol, June 1, 2005; 288(6): F1213 - F1219.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
B. T. Andresen, K. Shome, E. K. Jackson, and G. G. Romero
AT2 receptors cross talk with AT1 receptors through a nitric oxide- and RhoA-dependent mechanism resulting in decreased phospholipase D activity
Am J Physiol Renal Physiol, April 1, 2005; 288(4): F763 - F770.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.